Get started
Author

Mayte Olave

Observed name: M.-T. Olave
ORCID: 0000-0002-6326-5992
Observed ORCID: 0000-0002-6326-5992
OpenAlex ID: A5086491036
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study
2015 · E. M. Ocio, P. Herrera, et al. · Haematologica · 40
PDF
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity
2015 · Ricardo García-Muñoz, Ascensión López-Díaz-de-Cerio, et al. · Immunologic Research · 16
S130: Preliminary Results of Quiwi: a Double Blinded, Randomized Clinical Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients With Newly Diagnosed Flt3-itd Wild-type Aml
2023 · Pau Montesinos, Rebeca Rodríguez-Veiga, et al. · HemaSphere · 14
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
2022 · Catia Simoes, Maria-Carmen Chillon, et al. · Blood Advances · 9
PDF
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry
2025 · Ana Alfonso-Pierola, David Martinez-Cuadrón, et al. · Leukemia · 3
Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones
2023 · Ana Alfonso Pierola, Beñat Ariceta, et al. · Blood · 3
PDF
Prognostic impact of variant allele frequency in intensively treated patients with NPM1 -mutated AML: a PETHEMA study
2026 · José Vicente Gil, Claudia Sargas, et al. · Blood · 1
Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals
2024 · Manuel Jorge Fernández Villalobos, Javier Ortiz, et al. · Blood · 1
Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy
2026 · Bruno Paiva, Leire Burgos, et al. · Leukemia
Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter study
2026 · José Vicente Gil, Claudia Sargas, et al. · Haematologica
Upfront CPX-351 Induction at 8 Spanish Hospital. Efficacy of CPX-351 in Everyday Clinical Practice and Increased Insight into Its Use in Younger Adults
2024 · Manuel Jorge Fernández Villalobos, Javier Ortiz, et al. · Blood
PDF
P531: Midostaurin Plus 7 + 3 or Quizartinib Plus 7 + 3 in Flt3-itd Mutated Aml
2023 · Mar Tormo, Marina Diaz-Beya, et al. · HemaSphere
AML-122 Midostaurin Maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: A “Real-Life” Multicenter Study
2022 · Adolfo de la Fuente, Marina Diaz Beya, et al. · Clinical Lymphoma Myeloma & Leukemia
Poster: AML-122 Midostaurin Maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: A “Real-Life” Multicenter Study
2022 · Adolfo de la Fuente, Marina Diaz Beya, et al. · Clinical Lymphoma Myeloma & Leukemia
Immunotherapy with LAK Cells and Anti-CD20 Monoclonal Antibodies for Follicular Lymphoma: Enhanced Antibody-Dependent Cell Cytotoxicity of LAK Cells in Association with GA101 Rather Than Rituximab
2012 · Carlos Panizo, Susana Inoges, et al. · Blood
Works count: 15
Citation count: 87
H-index: 4
I10-index: 3
Year
Topic
Type